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Abstract
Purpose of review—Allogeneic hematopoietic cell transplantation (HCT) is a life-saving 
therapy for hematological and non-hematological diseases. Cord blood (CB) is a source of 
transplantable hematopoietic stem cells (HSCs), but limited numbers of HSCs in single CB units, 
which may cause delayed neutrophil, platelet, and immune cell reconstitution, is a major problem 
for efficient transplantation. Ex vivo expansion and enhanced homing of CB HSC may overcome 
this disadvantage and improve its long-term engraftment. Here, we discuss the role of nuclear 
hormone receptors (NRs) signaling in human CB HSC engraftment.
Recent findings—Antagonizing Retinoid acid receptor (RAR) signaling promotes human HSC 
expansion and increases myeloid cell production. CB CD34+ cells expanded by SR1 promotes 
efficient myeloid recovery after transplantation compared with control groups, and leads to 
successful engraftment. Short-term treatment of glucocorticoids enhances homing and long-term 
engraftment of human HSCs and HPCs in NSG mice. PPARγ antagonism expands human HSCs 
and HPCs by preventing differentiation and enhancing glucose metabolism. These findings 
demonstrate that NR signaling components might be promising targets for improving human CB 
HCT.
Summary—Better understanding of molecular mechanisms underlying human HSC expansion 
and homing mediated by NR signaling pathways will facilitate enhanced HCT efficacy.
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INTRODUCTION
Homeostasis of hematopoiesis is maintained by intrinsic and extrinsic signals by 
hematopoietic stem (HSC) and progenitor (HPC) cells, rare immature cell populations 
residing in microenviromental niches [1–3]. HSC self-renew, or differentiate through HPC 
into all mature blood cells throughout [4]. Human HSC are major contributors for HCT 
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[5,6]. Once infused into peripheral blood of recipients, HSC and HPC migrate and engraft in 
bone marrow (BM) niches, where a new hematopoietic system builds up [7,8]. Three major 
sources of HSC for HCT are: BM, peripheral blood and CB [9,10]. Compared with the other 
sources, CB has advantages, including ready availability, less strict HLA matching 
requirements, lower incidence of graft vs. host disease and virus infection, and low 
probability of relapse among patients with minimal residual disease [11–13]. However, 
delayed hematopoietic recovery and immune reconstitution due to limited numbers of HSCs 
are major limiting factors preventing the wider use of HCT based cell therapy. Progress to 
improve CB HSC engraftment and reconstitution includes mitigating effects of Extra 
Physiologic Oxygen Shock/Stress (EPHOSS) during cell collection [14], ex vivo expansion 
of HSC [15–17*] and enhancing HSC homing efficiency [18].
Nuclear hormone receptors (NR) are transcription factors which regulate expression of target 
genes by binding to specific response elements in the transcription units [19,20]. NR, 
consisting of 48 members in humans, are activated by steroid hormones such as 
glucocorticoids and estrogen, or non-steroid hormones such as retinoic acid, vitamin D, and 
thyroid hormones. NR members share a similar structure, composed of a highly variable 
A/B transactivation domain, a conserved DNA binding domain (C domain), a nuclear 
localization signal containing D domain and a relatively conserved ligand binding E domain 
[19,20]. Upon ligand binding, the conformation of NR changes and a repressor complex 
such as NCoR and SMRT corepressor disassociate from NR, followed by recruitment of 
transactivation complexes with histone acetyltransferase (HAT) activity and other 
transcription machinery, thus facilitating transcription of target genes[21]. NR are involved 
in physiological processes including: proliferation [22], differentiation [23,24], development 
[25] and metabolism [26,27]. To treat diseases caused by dysfunction of NR, synthetic 
agonists and antagonists of NR were developed to modulate its activity [28]. These 
diversified synthetic ligands help explore novel biological functions of NR in humans.
Here, we summarize recent progress regarding enhancing human HSC and HPC engraftment 
by modulating NR signaling.
RETINOID ACID SIGNALING AND HUMAN HSC EXPANSION
Retinoid acid receptor (RAR) serves as the nuclear receptor for all-trans retinoid acid 
(ATRA), the biologically active form of retinol (vitamin A) [29]. There are three different 
subtypes of RAR (α, β, γ), and each is alternatively spliced into at least two distinct 
isoforms [30]. Although RAR is highly conserved between mouse and human, functioning 
of RAR signaling in murine and human HSC homeostasis is quite different. RARα knockout 
mice show no abnormal phenotype of HSCs and HPCs, while HSC numbers are 
significantly reduced in RARγ knockout mouse BM [31]. BM HPC numbers are increased 
in RARγ knockout mice compared with wild type animals, suggesting that RARγ might 
regulate differentiation of their HSCs. Meanwhile, ATRA ex vivo treatment enhances 
repopulating capability of murine BM Lineage−Sca-1+c-Kit+ (LSK) cells, effects dependent 
on RARγ [31]. Physiological ATRA is derived from retinol, which is not synthesized by 
animals but is obtained from food (vegetables, fruits, animal livers) [32], so HSC 
homeostasis can be affected by availability of retinol in food. ATRA treatment protects 
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dormant HSCs from stress induced activation by restricting protein synthesis and reactive 
oxygen species (ROS) generation [33**]. Numbers of dormant HSCs in retinol free diet fed 
mice, in which the retinoid acid reservoir is depleted, is significantly reduced [33**].
RAR usually forms a heterodimer with retinoid X receptor (RXR) [34]. RXRα signaling 
negatively regulates granulocyte development from HSCs and HPCs in humans and mice 
[35], while in vivo hematopoiesis in RXRα knock out mice is normal [36]. Since there are 
two other isoforms of RXR (RXRβ, RXRγ) [30], normal hematopoiesis of RXRα knock out 
mice might be due to functional redundancy of different isoforms. It would be interesting to 
explore roles of RXR signaling in HSC self-renewal and maintenance using distinct RXR 
isoform double or triple knock out mice, since little is known of RXR in mouse and human 
HSC homeostasis.
Although activation of RAR signaling positively regulates development and function of 
mouse embryonic and adult HSC [31, 37, 38], human CB HSC self-renewal appears 
negatively modulated by the RAR pathway. Aldehyde dehydrogenase (ALDH) is a key 
enzyme in the RA synthesis pathway in vivo, and is characterized as a marker of HSCs and 
other tissue stem cells [39–41]. There are many ALDH isoforms. ALDH1 is considered the 
major isoform in HSCs and HPCs [42,43]. Treatment of human BM and CB CD34+CD38− 
cells with diethylaminobenzaldehyde (DEAB), an ALDH inhibitor, enhances expansion and 
maintenance of HSCs and HPCs, as well as the in vivo frequency of SCID-repopulating cells 
(SRCs) in immune-compromised NOD/SCID mice [43]. Enhanced expansion of HSCs by 
DEAB can be reversed by RA induced differentiation [43]. Although HSCs themselves have 
the capability to convert retinol to RA [44], it would be interesting to determine whether 
inhibition of ALDH in HSCs or HPCs leads to down-regulation of RA signaling, and thus 
stimulates human HSC expansion and maintenance. BM stromal cells secrete CYP26 in the 
serum to inactivate and prevent RA signaling, and thus regulate human HSC self-renewal 
[45], suggesting that modulating RA signaling by targeting microenviromental niches 
represents a promising way to enhance ex vivo human HSC expansion. Treatment of 
CD34+CD38− cells with LG1506, a selective RXR modulator, enhances human HSC and 
HPC expansion and long-term engraftment in NOD/SCID mice [46]. Mechanistically, once 
binding with LG1506, the RXR-RAR complex recruits silencing mediator of retinoic acid 
and thyroid hormone receptor (SMRT) corepressors to promoters of target genes such as 
CD38, thus inhibiting differentiation of HSCs [46]. Recently, it was found that RARα 
antagonist increases myeloid cell production and promotes expansion of human HSCs, while 
RARγ antagonist had no effect due to different sensitivity to ATRA [47]. RXR forms 
heterodimers with other NRs, including liver X receptor (LXR), thyroid hormone receptor 
(THR), vitamin D receptor (VDR), peroxisome proliferator-activated receptors (PPARs). 
Future studies should characterize roles of these RXR heterodimers in human HSC 
maintenance and engraftment.
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GLUCOCORTICOID SIGNALING IN HOMING AND ENGRAFTMENT OF 
HUMAN HSCS
Glucocorticoid (GC) receptor (GR) is a member of the steroid nuclear hormone receptor 
subfamily, which also includes mineralocorticoid receptor (MR), estrogen receptor (ER), 
androgen receptor (AR), and progestogen receptor (PR) [19]. Unliganded GR resides in the 
cytoplasm and is complexed with HSP90 and HSP70 [48]. Upon binding with GC, GR 
translocates into the nucleus and binds to GC response elements (GREs) in transcription 
units of target genes [49]. Co-activators such as SRC-1and CBP/p300 are recruited by 
activated GR, thus facilitating transcription of target genes [49]. GC/GR signaling is 
involved in many physiological processes, including carbohydrate metabolism, energy 
homeostasis, development and immune function [48]. GC levels are controlled by 
hypothalamic-pituitary-adrenal (HPA) axis in vivo [48]. In mouse and rat, the major 
endogenous GC is corticosterone, while in primates including humans the endogenous active 
GC is cortisol (or hydrocortisone) [50]. There are many synthetic GCs, such as 
dexamethasone, prednisone and fluticasone, which have been widely used as FDA approved 
drugs for anti-inflammation, allergy or asthma [48,51].
GCs regulate erythropoiesis. Co-culture with GCs in vitro promotes proliferation of 
erythroid progenitors [52]; in vivo, GR signaling is essential for stress-induced expansion of 
erythroid progenitors [52]. GR synergizes with PPARα promoting self-renewal of erythroid 
progenitor cells [53]. GC/GR signaling also plays pivotal roles in HSC homeostasis, 
including HSC production, HSC mobilization and HSC homing. During embryonic 
zebrafish hematopoiesis, serotonin regulates formation of HSCs and HPCs via HPA axis-
mediated GR activation [54*]. Upon developmental hypoxic stress, HIF-1α is activated and 
induces neuronal serotonin synthesis to regulate cortisol-dependent production of HSCs and 
HPCs [54*]. Whether HPA-GR mediated HSC and HPC production is conserved in adults, 
needs further study. The central nervous system not only regulates HSC formation, but also 
regulates HSC mobilization via the HPA axis. HPA-GR signaling induced by muscarinic 
receptor type-1 (Chrm1) in hypothalamus is essential for G-CSF induced HSC and HPC 
mobilization [55*]. Mechanistically, physiological concentrations of GCs promote migration 
of HSCs and HPCs by modulating actin polymerization and microtubule assembly [55*]. 
However, administration of high dose GCs significantly suppresses egress of HSCs and 
HPCs mobilized by G-CSF [55*]. It is unknown if this GCs dependent mobilization of G-
CSF is conserved in humans. Interestingly, GR is highly expressed in human CB CD34+ 
HSCs and HPCs, suggesting that GC/GR signaling might play a role in human HSC 
physiological function [56**]. In a compound screen to search for chemical candidates 
which enhance human HSC and HPC homing, dexamethasone was identified as a significant 
enhancer of CXCR4 expression and SDF1/CXCR4 axis-mediated chemotaxis [56**]. Short-
term pretreatment of CB CD34+ cells with other synthetic GCs including Flonase 
(fluticasone propionate), cortisol (hydrocortisone), and Medrol (methylprednisolone) 
promoted CXCR4 expression and chemotaxis of HSCs and HPCs [56**]. Flonase pretreated 
CB CD34+ cells manifested significantly enhanced SRCs, and enhanced human cell 
chimerism in primary and secondary recipient NSG mice, demonstrating effects of GCs on 
long-term repopulating, self-renewing HSC in CB cells [56**]. Upon GCs treatment, 
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cytoplasmic GR in CB HSCs and HPCs was activated. Activated GR translocated into the 
nucleus and bound to GREs in the human CXCR4 transcription unit (Fig. 1). SRC1/p300 
histone acetyltransferase complex was recruited to promote histone H4 acetylation 
associated with CXCR4, thus facilitating transcription and expression of CXCR4 in CB 
HSCs and HPCs. Unexpectedly, CBP was not involved in this process although in most case 
p300 and CBP function as a complex, further suggesting cell type and context specific 
effects of GC signaling. There are two isoforms of CXCR4 (CXCR4-A and CXCR4-B) in 
human cells due to alternative splicing. The promoters of CXCR4-A and CXCR4-B are 
totally different. The GRE locates in the promoter of CXCR4-A and the first intron of 
CXCR4-B. Since mRNA levels of CXCR4-A and CXCR4-B are significantly upregulated 
(our unpublished data), it would be interesting to know if there are functional differences 
between these two human CXCR4 isoforms in migration and homing of HSCs and HPCs. 
There is no GRE throughout the mouse Cxcr4 transcription unit, and Cxcr4 expression and 
SDF-1 induced chemotaxis of mouse BM HSCs and HPCs remain unchanged upon GC 
treatment [56**]. Whether GC pretreatment of mouse BM HSCs and HPCs enhances their 
homing and engraftment by mechanisms independent of the SDF-1/CXCR4 axis needs 
investigation.
ANTAGONIZING PPARγ SIGNALING EXPANDS HUMAN HSCS
The peroxisome proliferator-activated receptors (PPARs) family consists of three subtypes, 
PPARα, δ/β and γ. They are ligand-dependent transcription factors regulating genes 
involved in energy metabolism [57]. PPARα is highly expressed in liver and other tissues/
cells with a high fatty acid oxidation (FAO) rate, and mainly regulates lipid and lipoprotein 
metabolism [57]. Of interest, PPARα activation promotes expansion and self-renewal of 
erythroid progenitors [53]. Whether this process is dependent on FAO remains unknown. 
PPARδ is mainly involved in FAO in skeletal and cardiac muscles [57]. PPARδ dependent 
FAO regulates asymmetric division of mouse HSC, and thus is essential for HSC 
maintenance [58]. PPARγ is mainly expressed, but not restricted, in adipose tissue, and 
mediates transcription of genes involved in adipogenesis, lipid metabolism and glucose 
homeostasis [59].
In a compound screen, we found that PPARγ antagonist GW9662 significantly promotes ex 
vivo expansion of human CB HSCs and HPCs in RPMI1640 medium containing 10% fetal 
bovine serum (FBS) and cytokines (TPO, SCF, FLT-3L) [60**]. PPARγ is highly expressed 
in human CB HSCs, and knockdown of PPARγ in CB CD34+ cells enhances ex vivo 
expansion of HSCs, suggesting that PPARγ signaling functions as a negative regulator of 
human HSC self-renewal [60**]. Mechanistically, antagonizing PPARγ down-regulates 
differentiation associated genes, including CD38, CD1d, HIC1, FAM20C, DUSP4, DHRS3 
and ALDH1A2, and a negative regulator of glycolysis, FBP1[60**]. It has been shown that 
inhibition of ALDH1A2 significantly promotes expansion and maintenance of CB HSCs 
[43], which demonstrates that antagonizing PPARγ expansion of CB HSCs may act in part 
by preventing RA-induced differentiation. Importantly, PPARγ antagonism promotes 
glycolysis of CB HSCs and HPCs, while it has no effect on mitochondria metabolism 
[60**]. Loss of function of FBP1 was sufficient to expand CB HSCs and HPCs which was 
dependent on glucose metabolism. Antagonizing PPARγ-FBP1 signaling had no effect on 
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expansion and glucose metabolism of CB HSCs and HPCs when CD34+ cells were cultured 
in StemSpan™ Serum-Free Expansion Medium II (SFEM II) (our unpublished data). 
Interestingly, expression of PPARγ and FBP1 is greatly downregulated, while glycolysis is 
significantly enhanced when CD34+ cells are ex vivo cultured in SFEM II compared with 
10% FBS containing RPMI1640 regular medium (our unpublished data), suggesting that 
PPARγ-FBP1 signaling is repressed by unknown ingredients in SFEM II. These findings 
indicate that the PPARγ-FBP1 axis might function as a metabolic switch for expansion and 
self-renewal of CB HSCs and HPCs (Fig. 2).
Inhibition of FBP1 enhances glucose metabolism in many types of cancer cells, while 
overexpression of FBP1 suppresses growth of cancer cells by compromising glycolysis 
[61,62]. It is unknown if leukemia cell growth is dependent on glucose metabolism activated 
by suppressing FBP1, and if inhibition of FBP1 impairs mitochondria metabolism in 
leukemia. PPARγ agonist glitazones decreases expression of STAT5 target genes, HIF2α 
and CITED2, and disrupts quiescence and stemness of chronic myeloid leukaemia (CML) 
stem cells LSCs [63]. Further studies are needed to determine if PPARγ activation impairs 
glucose metabolism by increasing FBP1 expression in CML LSCs. In primates infected by 
human and simian immunodeficiency viruses, the multipotent potential of their HPCs is 
disrupted, which is dependent on repression of STAT5 by ectopic activation of PPARγ [64]. 
Whether STAT5 signaling is involved in expansion of CB HSCs and HPCs by antagonizing 
PPARγ needs study. Knockdown of PPARγ in Fancd2 deficient murine HSCs significantly 
enhances their repopulating capability in recipient mice, while loss of function of PPARγ in 
wild type murine HSCs has no significant change on their engraftment [65*]. PPARγ 
antagonism has no effect on expansion of mouse BM HSCs and HPCs, and doesn’t 
downregulate expression of differentiation associated genes and Fbp1 in mouse BM lineage 
negative cells [60**]. PPARγ and its co-activators are upregulated in human FANCD2-
deficient lymphoblastic cell lines and primary Fanconi patient samples [65*]. Future studies 
should determine the possible role of FBP1-mediated glucose metabolism and mitochondria 
metabolism in FANCD2-deficient HSCs.
CONCLUSION
Transcriptional regulation is one key intrinsic mechanism underlying human HSC expansion 
and self-renewal. As important members of transcription factors, NRs including RAR, GR 
and PPARγ play significant roles in expansion, self-renewal, homing and engraftment of 
human CB HSCs. Sufficient HSC numbers and efficient HSC homing are pivotal for 
successful clinical CB HCT, especially in adults. The more we know about molecular 
mechanisms of CB HSC self-renewal and homing, the better efficacy we can achieve in CB 
HCT clinical trials. Overexpression of Musashi-2 (MSI2), encoding an RNA binding 
protein, significantly promotes expansion of CB HSCs by suppressing aryl hydrocarbon 
receptor (AhR) signaling [66*]. Simultaneous transplantation of an SR1 (AhR antagonist) 
expanded CB-derived CD34+ cell population and an unmanipulated CB unit significantly 
promoted faster recovery of neutrophils and platelets after infusion [17*]. It would be of 
interest to determine the efficacy of combining SR1 with NR ligands, especially the homing 
enhancer Flonase in CB HCT. Recently, transplantable human HSCs have been successfully 
reprogrammed from iPS and endothelial cells [67,68**]. Can engraftment of these 
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reprogrammed HSCs be enhanced by modulating NR signaling? Since many NR ligands are 
FDA approved drugs, NRs represent promising targets for enhancing engraftment of human 
CB HCT.
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KEY POINTS
• Antagonizing RAR signaling increases myeloid cell production and promotes 
human HSC expansion and engraftment by inhibiting differentiation.
• Attenuating AhR signaling enhances human HSC expansion, and SR1 
expanded HSCs and HPCs show significant faster recovery of neutrophils and 
platelets in clinical study of HCT.
• Glucocorticoid pretreatment of human HSCs and HPCs enhances their 
homing and engraftment capability in NSG mice.
• PPARγ antagonism promotes self-renewal and engraftment of human HSCs 
and HPCs by switching on FBP1-repressed glucose metabolism and 
preventing differentiation. PPARγ is ectopically activated in primary fanconi 
patient samples, and PPARγ signaling might be an effective target in therapy 
of fanconi patients.
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FIGURE 1. 
Glucocorticoid (GC) pretreatment enhances homing and engraftment of human CB HSCs/
HPCs by transcriptionally increasing CXCR4 expression. GC activates glucocorticoid 
receptor in the cytoplasm, and GC-GR complex translocates into the nucleus and binds as a 
dimer to the GC response element in CXCR4 transcription unit. SRC1-p300 histone 
acetyltransferase complex is recruited to enhance histone H4 (H4K5 and H4K16) 
acetylation, thus facilitating transcription of CXCR4 in CB HSCs/HPCs [56**].
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FIGURE 2. 
PPARγ functions as a negative regulator of human CB HSC maintenance and expansion. 
During ex vivo culture in regular medium (RPMI1640+10% FBS+Cytokines), PPARγ 
signaling is activated. Activation of PPARγ increases expression of differentiation 
associated genes including CD38, CD1d, HIC1, FAM20C, DUSP4, DHRS3 and ALDH1A2; 
and a negative regulator of glucose metabolism FBP1. HSCs/HPCs will not be well 
maintained and expanded due to increased differentiation and repressed glucose metabolism. 
Antagonizing PPARγ signaling enhances maintenance and expansion of human HSCs/HPCs 
by preventing differentiation and switching on FBP1-repressed glycolysis [60**].
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